Chronic obstructive pulmonary disease and cardiovascular disease: mechanistic links and implications for practice
T Maeda, MT Dransfield - Current Opinion in Pulmonary Medicine, 2024 - journals.lww.com
COPD and cardiovascular disease have complicated interrelationships. Further mechanistic
studies may lead to defining better targets for interventions. Education for medical …
studies may lead to defining better targets for interventions. Education for medical …
Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
F Lucà, F Oliva, MG Abrignani, SA Di Fusco… - Journal of Clinical …, 2024 - mdpi.com
Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable
heterogeneity in both phenotypic and pathophysiological features, with a growing incidence …
heterogeneity in both phenotypic and pathophysiological features, with a growing incidence …
[HTML][HTML] Cardiovascular events after exacerbations of chronic obstructive pulmonary disease: Results from the EXAcerbations of COPD and their OutcomeS in …
S Calabria, G Ronconi, L Dondi, L Dondi… - European Journal of …, 2024 - Elsevier
Introduction Exacerbations of chronic obstructive pulmonary disease (COPD) can increase
the risk of severe cardiovascular events. Objective Assess the crude incidence rates (IR) of …
the risk of severe cardiovascular events. Objective Assess the crude incidence rates (IR) of …
SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting
SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More
news from American Heart Association Scientific Meeting | European Heart Journal …
news from American Heart Association Scientific Meeting | European Heart Journal …
[引用][C] Heart failure with preserved and reduced ejection fraction: comorbidities, therapies and cause-specific outcomes
A Shahim - 2024 - Inst för medicin, Solna/Dept of …
[引用][C] Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease—No heterogeneity
C Hage, LH Lund - European Journal of Heart Failure, 2023 - Wiley Online Library
In this issue of the Journal, Butt and colleagues present a pre-specified analysis of
dapagliflozin's safety and efficacy in patients with heart failure (HF) and preserved (HFpEF) …
dapagliflozin's safety and efficacy in patients with heart failure (HF) and preserved (HFpEF) …
[引用][C] November 2023 at a glance: Focus on cardiogenic shock, post‐discharge outcomes and cardiomyopathies
Figure 1 Adverse in-hospital events in patients treated with Impella, veno-arterial
extracorporeal membrane oxygenation (VA-ECMO) and Impella and VA-ECMO combined …
extracorporeal membrane oxygenation (VA-ECMO) and Impella and VA-ECMO combined …